Dabigatran, a direct thrombin inhibitor, is licensed for the prevention of venous
thromboembolism after knee and hip replacement, the prevention of stroke and systemic …

Dabigatran etexilate, a direct thrombin inhibitor, has become an alternative to warfarin for
stroke prevention in patients with nonvalvular atrial fibrillation. There remains a concern …

Objective: Dabigatran etexilate is a novel oral anticoagulant with several advantages over
warfarin such as no need for routine monitoring and fewer drug interactions. This drug was …

Objective: To review, analyze, and critique dabigatran etexilate's approved uses as an
anticoagulant. Data Sources: Literature searches were performed via MEDLINE …

Warfarin is an oral anticoagulant for treatment and prevention of venous and arterial
thromboembolism. It requires regular monitoring and patient adherence to a variety of …

Dabigatran (Pradaxa) is a new oral, direct, selective and reversible thrombin inhibitor (factor
IIa) acting as anticoagulant. Pradaxa does not require monitoring or dose adjustment, except …

Introduction: Stroke and venous thromboembolism (VTE) affect millions of patients. The
vitamin K antagonist, warfarin, has been the main oral anticoagulant used to treat these …

BACKGROUND: Until recently, warfarin was the only oral anticoagulant available in the
United States. Its narrow therapeutic index, interpatient variability in dose response, and …

Background: The superiority of dabigatran has been well proven in the standard dosing
regimen in prevention of stroke and systemic embolism in patients with non-valvular atrial …

Thrombin is a key enzyme in the blood coagulation cascade and a major factor in the
initiation and propagation of thrombosis. Thrombin inhibition therefore represents a …